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ABSTRACT 
Introduction: Onchocerca volvulus infects in excess of 15 million people. The vectors are 
Simulium blackflies, varieties of which differ in their ecologies, behaviour and vectorial 
abilities. Control of the vectors and mass administrations of ivermectin have succeeded in 
reducing prevalences with elimination achieved in some foci, particularly in Central and 
southern America. In Africa, progress towards elimination has been less successful. 
Areas covered: Even with community directed treatment with ivermectin (CDTI), control 
has been difficult in African areas with initial prevalences in excess of 55%, especially if only 
annual treatments are dispensed. This is partly attributable to insufficient coverage, but the 
appearance of incipiently resistant non-responding parasites and lack of attention to vector 
biology in modelling and planning outcomes of intervention programmes have also played 
their parts, with recrudescence now appearing in some treated areas. 
Expert commentary: The biology of onchocerciasis is complex involving different vectors 
with differing abilities to transmit parasites, diverse pathologies related to geographical and 
parasite variations and endosymbionts in both parasite and vector. Modelling to predict 
epidemiological and control outcomes is addressing this complexity but more attention needs 
to be given to the vectors’ roles to further understanding of where and when control measures 
will succeed.  
 
KEYWORDS: Onchocerca volvulus • Simulium damnosum complex • vector biology • 
ivermectin • doxycycline • moxidectin •  
 
  
 
 
1. Introduction 
The parasitic disease onchocerciasis or “river blindness” is caused by the filarial worm 
Onchocerca volvulus and is transmitted by blackflies of the genus Simulium.  The disease is 
found in sub-Saharan Africa, the Yemen and in Central and South America. In sub-Saharan 
Africa about 15 and a half million people may still be infected [1]. A further half a million 
were at risk in Latin America [2] but recent control programmes have reduced this number 
considerably, with only about 27,000 needing preventive chemotherapy in Brazil and 
Venezuela [3]. Severe symptoms include punctate and sclerosing keratitis in the anterior 
segment and optic nerve atrophy in the posterior segment and, at worst, the infection leads to 
bilateral blindness. In addition, onchocerciasis causes serious skin conditions such as severe 
itching, erythematous rashes, de-pigmentation including “lizard skin”, secondary infections 
after itchy areas are scratched, palpable nodules containing the adult worms, “hanging groin” 
and the condition known as “sowda”. There are also associations between onchocerciasis and 
epilepsy and dwarfism and, in addition, there is circumstantial evidence that the affliction 
known as “nodding disease” is associated with onchocercal infections [4]. Excess mortality 
attributable to onchocerciasis has been reported [5,6,7]. Diagnosis is by finding microfilariae 
in skin snips, usually from the iliac crest, by immunological and molecular techniques and, in 
severe cases, by observing microfilariae within the eye or from biopsies of excised nodules. 
  There is a variety of factors that affect or could affect the transmission of the disease. These 
include (1) rates of vector-man contact and lengths of time that exposure to infected vectors 
persists; (2) the parasite reservoir within human hosts; (3) the identity of the vector; (4) the 
ecology of the vector, especially regarding whether it is perennial or seasonal at a 
transmission site; (5) the vectorial efficiency of the vector and factors affecting it; (6) the 
presence or absence of endosymbiotic Wolbachia bacteria in either or both of the vector and 
the parasite; (7) variation between the parasite populations being transmitted and (8) variation 
in the immunity of the human hosts to parasite challenge, which may be affected by 
zooprophylaxis in the presence of the bovine parasite Onchocerca ochengi [8,9]. Means to 
interrupt transmission to achieve infection control include (a) vector control using larvicides 
sprayed upstream of the insects’ breeding sites in rivers or streams or by other means such as 
placing of briquettes impregnated with larvicide in breeding sites or vegetation control to 
remove larval supports; (b) nodulectomy, involving the excision from patients of sub-
cutaneous nodules harbouring adult parasites; (c) mass drug administration (MDA) of 
microfilaricidal drugs such as ivermectin, now by community-directed treatment with 
 
 
ivermectin (CDTI); (d) treatment with macrofilaricides and (e) various combinations of two 
or more of procedures (a) to (d). In this review, the salient features of the above topics are 
summarised and explanations are given of some of the constraints that can limit the 
effectiveness of actual or potential interventions be they against the vectors or the parasite. 
First,  where onchocerciasis has been wholly or partially interrupted is briefly reviewed, to 
permit concentration on the geographical zones where the disease remains a major problem 
and where the lessons to be learnt for infection control from knowledge of the factors 
affecting transmission are most in need of implementation. The focus will thus be on African 
problems where CDTI has yet to prove its full potential in contrast to situations in the 
Americas where it has been successful. Possible reasons for this difference will be addressed.  
 
2. The Vectors 
2.1. Sub-Saharan Africa and the Yemen 
In most of sub-Saharan Africa and the Yemen, the vectors are members of the Simulium 
damnosum complex. Exceptions include S. woodi and other members of the S. neavei group, 
including S. neavei itself, which transmit the disease in parts of East Africa such as Uganda 
and have their immature stages phoretic on freshwater crabs (family Potamonautidae), and S. 
albovirgulatum which is a vector in the central basin region of the Democratic Republic of 
Congo [10]. The S. damnosum complex comprises at least 63 cytoforms, many of which have 
been given formal scientific names; 32 of the forms are known to be anthropophilic, a further 
three are presumed to be, and 22 are proven vectors [11]. At least two of these confirmed 
vectors (the Bioko form of S. yahense [12] and the Djodji form of S. sanctipauli [13]) have 
been rendered extinct by vector control measures and it is suspected that the “Chutes Milo” 
form of S. soubrense has suffered the same fate [14].  
 
2.2. Central and South America 
In Mexico, the main vectors in the only known foci in Chiapas and Oaxaca States are 
members of the S. ochraceum and S. metallicum complex but the disease has now been 
eliminated from the country [15]. In Guatemala, where transmission has been interrupted, 
there were four main foci where the vectors are members of the S. ochraceum complex. In 
northern Venezuela, the main vectors in both the north-eastern and north-central foci are 
members of the S. metallicum complex, whereas in southern Venezuela the main vectors in 
the Amazonas/Bolivar focus are members of the S. guianense complex. That focus is 
 
 
contiguous with the Amazonas-Roraima or Amazônia focus in northern Brazil which has the 
same vectors (S. guianense complex and S. incrustatum) in highland areas, but in lowland 
parts of the Amazônia focus the main vectors are members of the S. oyapockense complex 
[16]. In the Minaçu focus in central Brazil, NNW of Brasilia, S. nigrimanum is suspected to 
be the main vector but there are other candidates [17]. In the Lópes de Micay focus of 
western Colombia, the main vectors are members of the S. exiguum complex, while in 
Ecuador the main vectors in the Esmeraldas / Pichincha focus are members of the S. exiguum 
complex and S. quadrivittatum.  
 
3. Interruptions of Transmission in Latin America: probably permanent 
cases 
The Onchocerciasis Elimination Program for the Americas (OEPA) has coordinated control 
efforts against the disease in 13 foci located in Brazil, Colombia, Ecuador, Guatemala, 
Mexico and Venezuela. OEPA is a consortium of those countries with the Pan American 
Health Organization, the ivermectin donor Merck & Co., Inc., the USA’s Centers for Disease 
Control and Prevention (CDC) and The Carter Center, Lions Clubs International Foundation 
and the Christian Blind Mission, all international Nongovernmental Development 
Organizations. Reliant only on MDA, the aim is to treat all affected populations two to four 
times a year [18,19]. The programme has been successful, claiming 85% coverage, and the 
extent of the successes is briefly described below, with elimination or interruption of 
transmission reported from 11 foci. A map of the 13 OEPA foci with progress up to 2011 was 
given by Gustavsen et al. [19], but they omitted  the Minaçu focus in Brazil which was not 
part of OEPA, as did Rodriguez-Perez et al. [20] who updated progress to 2013. 
Onchocerciasis elimination successes in the Americas according to country are as follows. 
Colombia: the disease has been declared as eliminated [21]; Ecuador: transmission has been 
eliminated [22]; Guatemala: the disease has been declared as eliminated [18]; Mexico: 
transmission has been eliminated [15] and northern Venezuela: transmission has been  
interrupted in the north-eastern focus and has been eliminated from the north-central focus 
[20, 23]. 
 
4. Incomplete interruptions of Transmission in Latin America 
Brazil: transmission is continuing in the Amazonas [24] and possibly in the Minaçu foci. 
Venezuela: transmission is continuing in the south focus where onchocerciasis remains in the 
 
 
indigenous Yanomami population inhabiting the Amazon rainforest on both sides of the 
Venezuela and Brazil border [24]. 
 
5. Interruptions of Transmission in Africa: probably permanent cases  
5.1. Equatorial Guinea 
In 2005 the unique endemic Bioko form of S. yahense [25] was eradicated from the island of 
Bioko (formerly known as Fernando Po), Equatorial Guinea, in the Gulf of Guinea [12]. 
Although MDA with ivermectin was underway and was making progress, the cessation of 
transmission there can be attributed to the vector elimination programme. This was achieved 
by a combination of applications by helicopter and ground-based spraying of the 
organophosphate insecticide temephos that was managed by the WHO African Programme 
for Onchocerciasis Control (APOC). A follow-up study in early 2014 has shown that no 
children less than 10 years old have been infected showing that disease elimination is in 
progress [26]. 
 
5.2. Ethiopia 
In the Tigray Region onchocerciasis has disappeared without any deliberate interventions 
against it, but probably as a result of human migrations and the introduction of commercial 
farming practices [27]. 
 
5.3. Kenya 
Davies [28] reviewed control attempts against Simulium spp. when he could report that a 
combination of vegetation removal and DDT had successfully stopped transmission in 
Kenya, where the vector S. neavei was eradicated from six foci between 1946 and 1955 
[29,3029]. 
 
5.4. Sudan 
The first evidence in East Africa that long-term CDTI alone can interrupt transmission of 
onchocerciasis was provided by the case of the Abu Hamed focus on the River Nile in Sudan, 
where ivermectin was first distributed annually in 1998. From 2006 onwards, treatments were 
increased to twice per annum and by 2011 no infections were found [31]. 
 
5.5. Uganda 
 
 
Successes in Uganda included use of DDT against S. damnosum in the Ruwenzori focus from 
1963 to 1977 and at Jinja, where the River Nile drains from Lake Victoria, in 1973. S. neavei 
was eliminated from the Itwara focus, also in Uganda and where annual distributions of 
ivermectin were not succeeding, using ground-based applications of temephos in the late 
1990s [32], followed by the disappearance of the disease by 2010 [33]. Onchocerciasis 
transmission by S. neavei was also interrupted in the Mpamba-Nkusi focus of Uganda by 
MDA that began in 1993 but the impact of vector control in 2002 was decisive as it led to the 
elimination of the vector by 2008 [34]. Similarly, vector control eliminated S. neavei in the 
Mt Elgon focus, perhaps assisted by environmental effects such as deforestation, and drug 
treatments were stopped there in 2012 after annual MDA since 1994 was increased to twice 
per annum in 2007 [35]. After MDA in the Wadelai focus, it was confirmed that 
onchocerciasis had been eliminated in 2010 but this was probably partly attributable to the 
earlier disappearance of the vectors for environmental reasons [36]. Elimination of S. neavei 
combined with MDA has stopped transmission in the Kashoya-Kitomi focus [37]. 
Transmission continues in the Kasese focus where the vector is S. kilibanum, a member of the 
S. damnosum complex [38]. 
 
6. Interruptions of Transmission in Africa: probably temporary 
6.1. Eleven countries in West Africa 
The rationale for the WHO Onchocerciasis Control Programme (OCP) was based on the 
prevailing notion that there was a difference between forest and savanna strains of the disease 
based on research by Duke and his colleagues [39], who developed the concept of Simulium-
Onchocerca complexes after finding incompatibilities between savanna vectors and forest-
derived parasites and vice versa. As there was also evidence that there was more blindness in 
savanna areas than in forest zones, where blindness was rarer, it was assumed that only the 
savanna form of the parasite was important in blinding onchocerciasis. Thus, with the 
objective of eliminating onchocerciasis as a disease of public health and socio-economic 
importance and prevent recrudescence, the initial plan was to use aircraft to treat only rivers 
where savanna vectors were present with the organophosphate larvicide temephos (Abate®) 
[40]. It was the biggest vector control programme ever mounted and its massive scale was 
partly based on experience gained from smaller operations after which vectors continued to 
re-appear from surrounding areas. The WHO Onchocerciasis Control Programme (OCP) 
began its campaign in seven different West African countries (Benin, Burkina Faso, Côte 
 
 
d’Ivoire, Ghana, Mali, Niger and Togo) in 1975 which, with later additions of more countries 
(Guinea, Guinea-Bissau, Senegal, Sierra Leone) and MDA of ivermectin, it continued until 
2002. The ivermectin (150 μg/kg of body weight, orally) was donated as Mectizan® 
(ivermectin-MSD) by Merck & Co. Inc. (Kenilworth, NJ, USA) and was freely available to 
OCP from 1989. The widespread benefits of the operation included the elimination of the 
disease as a public health problem (except in Sierra Leone because of civil strife), 600,000 
cases of blindness were prevented, 18 million children born in now-controlled areas spared 
from the risk of river blindness and 25 million hectares of land were made safe for cultivation 
and resettlement [18, 41]. Nevertheless, pockets of transmission remain where it was never 
successfully interrupted, as documented for Ghana [42] and where some patients do not 
respond to ivermectin [43,44]. Furthermore, there is a continuous threat of reinvasion of the 
OCP-controlled areas by infected vectors or by infected human migrants and recrudescence 
has now been reported in Burkina Faso, particularly in the Comoé valley where one site had a 
prevalence in excess of 71% in March 2010 [45]. 
  
6.2. Mali 
After 17 years of annual distributions of ivermectin in the R. Bakoye focus, including being 
part of the western extension of the OCP where MDA without any vector control was 
initiated in 1988, followed by 4 years of no treatments, the prevalence of microfilariae and 
infectivity levels in the vectors, estimated by pool-screening methods [46], had both declined 
to zero [47].  In the R. Faleme focus that straddles the Mali / Senegal border, overall 
prevalence fell from 34% to 0.84% after 15 years of annual treatments and dropped to 0.07% 
a further 2.5 to 5 years later. There were still some infections present in vectors so complete 
elimination was not achieved, but this was claimed as there was no evidence of recrudescence 
of either infection or of transmission rates [47]. Time will tell if this achievement is 
maintained or if transmission resumes once infected vectors reinvade from neighbouring 
territories. 
 
6.3. Nigeria 
Tekle et al. [48] reported successful elimination after using ivermectin for 15 to 17 years in 
the Birnin Gwari Local Government Area (LGA) and in the Kauru and Lere LGAs of Kaduna 
State. The median initial prevalence was 52% and was reduced to zero in a sample of 3703 
patients following the APOC-led CDTI programme. As with the Malian case, time will tell if 
 
 
this achievement is maintained or if transmission resumes once infected vectors reinvade 
from neighbouring territories. 
 
6.4. Senegal 
In the R. Gambia focus, prevalences of onchocerciasis and vector infectivity rates were 
reduced to zero by six-monthly treatments for 14 to 16 years, from an initial level of 49.6% 
[47]. For details of the R. Faleme focus see under Mali (above). The same caveats about 
potential vector reinvasions into cleared areas of Mali and Nigeria also pertain for Senegal. 
 
6.5. Uganda 
Applications of DDT eliminated S. neavei in parts of the Kasowka-Bokwe  
subfocus within the Budongo forest of Uganda [49,50], but the vector has now returned [51]. 
 
7. Entomological factors important in transmission 
7.1. Man-vector contact rates 
Rates of microfilarial densities and blindness due to onchocerciasis in savanna regions tend to 
be higher in males than females [52] so, in addition to absolute rates of man-vector contact 
that will affect transmission rates, there are differences within human populations [53]. These 
have been attributed to gender- and age-related behavioural differences. Thus, in the Sudan 
savanna of North Cameroon, boys are subject to more than twice the exposure to vector bites 
as are girls and this gender-based difference is usually maintained later in life [54]. 
 
7.2. Vector competence and zoophily 
Vector competence differs between species and cytoforms. Amongst the South American 
forms, some of the differences can be ascribed to the presence or absence of cibarial teeth in 
the female insects’ mouthparts [55]. For those species such as S. ochraceum s.l., S. 
oyapockense s.l. and S. incrustatum that have these structures, the likelihood of microfilariae 
escaping into a fly’s abdomen undamaged is greater the more that are taken up by the fly, a 
relationship that is density dependent and species specific [56]. The armature protects flies 
from death if they take up an excessive number of microfilariae, which happens rapidly in 
these circumstances for species without the structure such as S. metallicum [57]. There are 
also many other interactions such as the effects of parasite loads on fly fecundity [58], fly 
survival, the availability to the flies of microfilariae from humans, the frequency distributions 
 
 
of Onchocerca within the flies, the survival of the worms within the flies (and thus the 
proportions of microfilariae that become established to develop into third stage infective 
larvae (L3s)) and the extent of the flies’ zoophily, all of which influence transmission 
dynamics [56,59].  
  Amongst the S. damnosum complex in Africa, there are many species that do not transmit 
onchocerciasis at all or do so very inefficiently. For example S. pandanophilum, S. kulfoense 
and S. soderense seem to be entirely zoophilic [11], whereas type 4 cytotypes of S. sirbanum 
can transmit but are also highly zoophilic [60,61]. The extent of zoophily in vectors studied 
in Ghana ranged from a human biting index (HBI, measured as proportion of meals taken on 
man) of 0.44 in S. squamosum cytoform E to 0.92 in the Beffa form of S. soubrense [62]. 
That study also revealed the extent of intraspecific variation in vectorial abilities as the 
human biting index of S. squamosum cytoform C was 0.86 (i.e. nearly twice that of cytoform 
E), thereby further emphasising the importance of correct vector identifications in studies of 
onchocerciasis transmission. This is also important for understanding transmission rates in 
different areas where the vectors may differ, which were summarised by Cheke & Garms 
[63]. For instance, in East Africa, S. kilibanum transmits at a rate of 19 L3s per 1000 biting 
flies, whereas the maximum value reported was for the Pra form of S. sanctipauli in Ghana 
with 191 [63]. The latter species is adapted to forest habitats, so the result is paradoxical since 
manifestations of the disease, particularly in terms of percentages of bilateral blindness, are 
more severe in savanna areas [64] where the transmission rates of the main vectors, S. 
damnosum s.str. and S. sirbanum were only 84 L3s per 1000 biting flies [63]. Furthermore, in 
Liberia, another forest vector, S. yahense, is associated with blindness rates of 2.1 to 8.9%, 
which together with other evidence led Cheke & Garms [63] to question the prevailing 
paradigm derived from Duke’s work [39] of there being forest and savanna strains of O. 
volvulus with contrasting epidemiological effects and transmitted as part of differing systems 
of Simulium-Onchocerca complexes. Whilst there certainly are geographical differences 
between epidemiological patterns it does not now seem plausible that they can be explained 
by a simple forest-savanna dichotomy, especially since molecular data have demonstrated 
gene flow from savanna to forest “strains” and the existence of admixed populations [64]  
There are, however, major differences between vectors not only regarding their vectorial 
abilities but also with respect to their behaviour and ecologies with implications for disease 
management. Regarding the vectorial abilities, the crude indices of numbers per 1000 biting 
flies or numbers per 1000 parous flies mask a complication that is linked to the paradox 
raised above. Flies adapted to predominantly forest habitats often harbour far more parasites 
 
 
per infected fly than do those adapted to mostly savanna zones. Thus, frequency distributions 
of numbers of parasites per fly in forest taxa, such as members of the S. sanctipauli sub-
complex and S. yahense, have longer tails and higher maxima than other forms [66]. This is 
reflected in lower values of the parameter k of the negative binomial distribution (NBD) 
when NBDs are fitted to frequency distributions of numbers of larvae of each of the different 
stages, meaning that the forest forms have more overdispersed, or clumped, parasite 
distributions than do their savanna cousins. In terms of mean numbers of L3 parasites per fly 
with L3s, the savanna S. damnosum / S. sirbanum have only 1.9 whereas the St. Paul form of 
S. soubrense boasts 6.6 [63]. These results are difficult to reconcile with the Onchocerca-
Simulium complex idea given that when forest-associated taxa such as the Beffa form of S. 
soubrense and the savanna-associated S. damnosum / S. sirbanum are biting the same human 
populations in sympatry the vectors retain their taxon-specific characteristic transmission 
patterns [66]. 
   Irrespective of variations in parasite loads, variation in the longevities of different species is 
also critical for transmission. Species with short life-spans have low parous rates and in some 
cases so few individuals live long enough for the parasites to develop to the infective stage 
that their vectorial efficiencies are low. For example, one of the reasons that the St.Paul form 
of S. soubrense is an inefficient vector is its low parous rate while, in contrast, some S. 
sirbanum may live for more than two months [67] and hence are capable of transmitting 
several times. This ability will also be affected by increased longevity in dry seasons and 
gonotrophic cycle lengths, for which evidence from both pteridine accumulation rates [68] 
and time series analysis [69] suggest may be longer in S. squamosum than in S. damnosum / 
S. sirbanum. A further complication is that parous rates are inversely density dependent [70]. 
   In some cases, such as with S. yahense in Liberia (see above), only one vector species is 
responsible for all of the transmission in a zone but more often vectors occur sympatrically, 
as in the above example, so that there are a mixture of species in biting populations. For 
instance, in the Dayi river at Kudzra and Wegbe in the Volta region of Ghana at least five 
different members of the S. damnosum complex (S. damnosum s.str., S. sirbanum, S. 
squamosum, S. yahense and S. sanctipauli) have been recorded simultaneously 
(supplementary data of [71]). This makes interpretation of transmission patterns and effects 
of control difficult without painstaking identifications of individual flies. For example, at 
Djodji (known as Pillar 83 in Ghana on the opposite side of the river) beside the Gban-Houa 
river (known as the Wawa river in Ghana) flies are still biting in the post-OCP era but 
monthly biting rates are less than they used to be (e.g. approx 7,000 versus approx 12,000 in 
 
 
February and March [72]). This is because most of the biting is now attributable to S. 
squamosum following the elimination by OCP of a more efficient vector (the Djodji form of 
S. sanctipauli) [13]. 
The forest-dwelling vector taxa are generally more sedentary than the savanna species, 
which are renowned for very long distance movements of 300km or more [73], so  vector 
control is easier to maintain in forests. In savannas  controlled zones are liable to be 
reinfested by immigrants from afar, a phenomenon that afflicted the OCP [73,74,75,76] 
which was resolved by extending the treated zones. Another problem that affected OCP was 
the development in some cytoforms of resistance to the insecticides of choice that was 
circumvented partly by introducing alternative larvicides and partly by a policy of rotating 
the ones in use [77]. 
 
7.3. Vectors and Wolbachia 
The endosymbiont Wolbachia is important in the pathology of cutaneous and ocular 
manifestations of onchocerciasis as the bacteria engender inflammatory reactions [78,79]. 
These Wolbachia are also crucial for the parasites’ survival, which is exploited in antibiotic 
treatments with doxycycline (see below). However, the significance of Wolbachia within the 
vectors has received less attention. A phylogenetically unique form of Wolbachia has been 
identified from S. squamosum E in Ghana [80], together with an associated bacteriophage 
that could potentially act as a vehicle for genetic modification of insect Wolbachia [81]. In 
addition to the finding of Wolbachia in S. squamosum E, the endosymbionts have also been 
found in another forest vector (S. yahense) and, rarely, in a third forest form (S. sanctipauli) 
but so far only once in a savanna vector (S. damnosum s.str.) (J. L. Crainey, pers. comm., 
January 2017) so, although speculative, it is possible that Wolbachia may play a part in how 
onchocerciasis is differentially transmitted by vectors from different biomes, given that 
Wolbachia can affect how mosquitoes transmit some pathogens. Further research on 
Wolbachia in different members of the S. damnosum complex is urgently needed to elucidate 
its role or roles, if any, in the transmission of onchocerciasis and its potential as a control 
agent, given that Wolbachia is now used to control mosquito vectors of the dengue virus and 
other pathogens.  
 
8. Treatments 
8.1. Microfilaricides 
 
 
Ivermectin, the mainstay of MDA and CDTI programmes, is contra-indicated in areas where 
the eye-worm Loa loa is also present [82], so alternative drugs are needed where O.volvulus 
and L. loa are sympatric and when a test and treat approach has demonstrated co-infection. 
Diethylcarbamazine is also contra-indicated because of the risk of a strong Mazzotti reaction 
and exacerbation of ocular pathology, but a combination of doxycycline and albendazole [83] 
or doxycycline alone [84] can be used under these circumstances. Apart from ivermectin, 
other microfilaricides include moxidectin, which has a longer-lasting effect than ivermectin 
and with little re-population [85] but it has yet to be licensed. Doxycycline, a macrofilaricide 
(see below) also has a deleterious effect on microfilariae as it inhibits their rate of 
development in vectors and so influences transmission rates [86]. There are also other reasons 
for seeking alternatives to ivermectin since Awadzi et al. [87,88] reported that some patients 
treated with the drug were not responding as expected since their microfilarial loads re-
populated rapidly, a phenomenon confirmed by Osei-Atweneboana et al. [43,44]. There is 
also evidence of incipient resistance in Cameroon [89,909]. Clearly, if common or spreading, 
the presence of non-responding parasites will increase the probability that transmission will 
continue or be enhanced. Other entomological issues related to ivermectin delivery concern 
the need to time interventions at the times when transmission is at its height. This is because 
modelling has shown that the timing of drug distributions in relation to seasonal transmission 
peaks has an impact on the period needed for a MDA programme to achieve maximum 
reductions in skin microfilarial loads [91]. The frequency of ivermectin treatments is also a 
factor. Indeed some failures of annual distributions to interrupt transmission [90,93,94,95]  
have led to the adoption by many health authorities of biannual treatments which have been 
shown to improve the efficacy of ivermectin, except in the case of sub-optimally responding 
parasites [96]. 
 
8.2. Macrofilaricides 
Doxycycline is the only usable macrofilaricide at present but the need for daily doses of 100 
or 200 mg orally for 4-6 weeks precludes its use in MDA or CDTI, plus it cannot be 
prescribed for pregnant women and children less than 8 years old. Doxycycline, being an 
antibiotic, functions by killing endosymbiotic Wolbachia within the adult worms. This leads 
to sterility of the worms and hence reduced production of microfilariae and the adults’ 
longevity declines from about 10 years to 2 to 3 years [97]. Doxycycline is also valuable as a 
potential drug for use where L. loa is sympatric with O. volvulus, since L. loa does not 
contain Wolbachia and so treatments do not lead to adverse reactions in co-infected patients. 
 
 
 
8.3. Compliance with treatments 
Despite some claims of very high rates of compliance in MDA or CDTI programmes, 
compliance is often less than adequate in many parts of Africa when it fails to reach the target 
of 65% [98]. There may also be discrepancies between officially released compliance 
estimates and results from questionnaires. For example, Kutin et al. [99] reported a 
compliance rate of only 24.4% in Ghana whereas other estimates from the same country 
based on official returns ranged from 50 to 90% [42] and 42–96% [96].  
 
9. Vector and parasite criteria for declarations of onchocerciasis 
elimination 
Larvicidal treatments were stopped in the OCP once transmission indices had reached a level 
of one infective larva per 1000 parous flies. Subsequently APOC, which has shifted its main 
aim from the control of onchocerciasis morbidity to elimination of the parasite reservoir, 
where feasible, with annual (or biannual) ivermectin MDA, proposed criteria for declarations 
of onchocerciasis elimination. These were that CDTI could be stopped once a microfilarial 
prevalence of <5% in all surveyed villages and <1% in 90% of such villages had been 
achieved, together with transmission indices of <0.5 infective larvae per 1000 dissected flies 
[100]. Computer models of onchocerciasis transmission have been used to estimate 
thresholds of parasite densities below which transmission would be so low as to lead to the 
collapse of the parasite population. Such transmission break points and similar thresholds 
were investigated with respect to MDA by Stolk et al. [101], who concluded that APOC’s 
operational thresholds need adjustment in relation to pre-control endemicity levels. This 
conclusion was based on comparisons of outputs from the individual-based simulation model 
ONCHOSIM [102] and a deterministic population model EPIONCHO [103]. Results from 
the latter were more pessimistic than those from the former and suggested that local 
elimination using CDTI, even biannually, would take more than 25 years at baseline 
endemicity levels >55%. Further model comparisons have been presented by Basáñez et al. 
[59] who also emphasised the need to adjust criteria for elimination based largely on 
elaborations of EPIONCHO. Both ONCHOSIM and EPIONCHO are complex models 
seeking to tackle most aspects of the biology and control of onchocerciasis, which include 
scenarios involving vector control and aspects of parasite establishment within vectors. 
However, they make no attempts to include vector population dynamics, which are treated as 
 
 
a fixed input (the annual biting rate, with an option for considering seasonal variations), nor 
what happens when different vector taxa, each with differing vectorial characteristics, are 
transmitting in sympatry. Thus, some of the most important factors in transmission are side-
lined and the biggest threat to onchocerciasis control programmes, reinvasion of infected 
vectors from outside controlled zones, is ignored. It is expected that future modelling work 
will remedy some of these omissions by including vector dynamics, following initial work 
linking them to EPIONCHO [104]. 
 
10. Vaccines for onchocerciasis 
Based on successful results using animal models, some candidate vaccines against 
onchocerciasis have been found [105,106] and further trials are planned. The potential 
deployment of a vaccine has been modelled and it was concluded that after 15 years of a 
childhood vaccination programme it would have a protective effect and be valuable for 
preventing re-emergence of the disease in areas cleared of the infection [107]. 
 
11. Expert Commentary 
Onchocerciasis remains an important cause of morbidity in parts of Brazil, Venezuela and 
Yemen and throughout much of sub-Saharan Africa despite more than 40 years of concerted 
control efforts.  Mass drug administration programmes in Africa have not been as successful 
as they have been in central and southern America because the African foci are larger, 
coverage and compliance are less good, incipient resistance to ivermectin has appeared in 
parts of Ghana and Cameroon, ivermectin is contra-indicated for 14 million people where 
loiasis is co-endemic and recrudescence is appearing in areas previously subject to intense 
vector control. Apart from some areas with initial prevalences of 55% or less, where local 
eliminations using MDA/CDTI have been reported, successful eliminations in Africa, such as 
those in Equatorial Guinea and Uganda have been driven by vector control. Thus, in future, 
renewed consideration needs to be given to localised vector control coupled with CDTI, 
especially in hyperendemic areas, and to vector migrations. 
 
12. Five-year View 
As progress towards elimination of onchocerciasis proceeds, there is a need to seek 
alternatives to ivermectin that are amenable to mass distribution, as incipient resistance to 
ivermectin may spread. The publication of the genome of O. volvulus [108] should assist this 
 
 
search. Means to improve coverage and compliance of CDTI and the discovery of a reliable 
macrofilaricide are also required, together with continuing research to find a vaccine. 
Although speculative at this stage, understanding of the roles of endosymbionts within 
vectors and of any taxon-specific differences between them could lead to breakthroughs in 
elucidating geographical variation in epidemiological patterns and pathologies and to new 
control techniques. Models describing dynamics of the human parasite need to be linked to 
sub-models of vector population dynamics and migrations. Future climate changes may lead 
to the disease spreading or contracting its geographical range according to rainfall and 
temperature shifts. 
 
13. Conclusion 
Before its closure APOC has altered its main aim from controlling onchocerciasis morbidity 
to eliminating the parasite reservoir, where feasible, with annual (or biannual) ivermectin 
distributions. The Expanded Special Project for Elimination of Neglected Tropical Diseases 
(ESPEN) now has the responsibility for oversight of onchocerciasis control [109]. To be 
successful, especially where prevalences exceed 55%, CDTI programmes such as those under 
ESPEN’s guidance need to ensure high levels of coverage and compliance combined with 
localised vector management and recognition of the reality of vector movements, particularly 
in savanna habitats. CDTI needs to be extended to all endemic areas, including hypoendemic 
zones. Elimination is unlikely to be achieved with reliance on a single drug but may be 
successful given new micro- and macrofilaricides and a vaccine. Modelling efforts to predict 
the outcomes of control programmes need to take more account of vector biology. 
 
14. Key Issues 
• In most onchocerciasis-endemic areas ivermectin is still efficacious against the 
microfilariae of Onchocerca volvulus and is being deployed successfully. 
• The potential for resistance to ivermectin spreading needs to be monitored and 
alternatives such as moxidectin developed for widespread use. 
• A macrofilaricide capable of being used in MDA programmes and / or a vaccine 
would substantially improve the chances of onchocerciasis elimination. 
• In contrast to successes in central and southern America, mass drug administration 
(MDA) in Africa is unlikely to succeed in areas with >55% prevalences without 
supplementary vector control or enhanced coverage of and compliance with MDA. 
 
 
• Treated areas are threatened by invasions of infected vectors from surrounding 
untreated areas 
• Correct vector identification and vector incrimination is crucial for understanding the 
epidemiology of onchocerciasis and vector population dynamics should be included in 
future modelling work designed to assist long-term planning and decision-making 
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